• LEARN MORE ABOUT KEYNOTE 695
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact
OncoSec Medical Incorporated
  • About
    • About
    • Join The Team
    • Management Team
  • Pipeline
  • Technology
    • Technology
    • Tavo
    • VLA
    • Combination Approach
    • Publications
  • Partnering
  • Patients
    • Patients
    • Resources
    • Expanded Access
    • Together Against Cancer
  • Investors
  • Media
  • Contact

Press Releases

Investors

Investors

  • Overview
    • Profile
    • Contacts
  • Events & Presentations
  • Analysts
  • Press Releases
    • Email Alerts
  • Financial Info
  • Stock Info
    • Quote
    • Charts
    • Historical Data
  • Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • FAQ
  • Press Releases

  • Email Alerts

OncoSec Announces Approval of $2.5 Million in NJEDA NOL Program Tax Benefits

Feb 23, 2021 9:00am EST

OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development

Feb 18, 2021 8:30am EST

OncoSec Strengthens Management Team With Two New Appointments

Feb 02, 2021 9:00am EST

OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein

Jan 27, 2021 9:00am EST

OncoSec Medical Closes $42.0 Million Public Offering of Common Stock

Jan 25, 2021 4:00pm EST

OncoSec Medical Announces Pricing of $42.0 Million Public Offering of Common Stock

Jan 21, 2021 8:30am EST

OncoSec Medical Announces Proposed Public Offering of Common Stock

Jan 20, 2021 4:35pm EST

OncoSec Enters into Option Agreement with Sirtex Medical to Co-Promote TAVO™

Jan 19, 2021 8:30am EST

OncoSec Announces First Patient Dosed in Phase 2 Trial of TAVO™ Plus OPDIVO® as Neoadjuvant Therapy for Melanoma

Jan 08, 2021 9:00am EST

OncoSec Strengthens IP Portfolio with Allowance of Two European Patent Applications Covering TAVO™ and Its Gene Electrotransfer Technology

Dec 10, 2020 9:00am EST
RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...43
Next
  • Email Alerts
  • Contacts
  • RSS News Feed
logo

Sign Up for our mailing list to stay current on all of our exciting new research and developments.

Get Email Alerts
OncoSec’s investigational products have not been approved or cleared by the FDA.

Links

  • About
  • Pipeline
  • Technology
  • Partnering
  • Patients
  • Media
  • Investors
  • Contact
  • KEYNOTE 695 CLINICAL TRIAL

Contact

New Jersey Headquarters
24 N. Main St
Pennington, NJ 08534

R&D Laboratories
3565 General Atomics Court #100
San Diego, CA 92121

p | 855.662.6732
f | 858.430.3832

Investors@OncoSec.com


© 2021 OncoSec Medical Incorporated. All Rights Reserved. Q12-003052-01 REV E.